Select a medication above to begin.
Qivigy (immune globulin human-kthm)
immune globulin (human)
Black Box Warnings .
Thrombosis
may occur with immune globulin products; risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, venous or arterial thrombosis history, estrogen use, indwelling central vascular catheter, hyperviscosity, and cardiovascular disease risk; thrombosis may occur in patients without risk factors; ensure adequate hydration before administration; give minimum dose at lowest infusion rate practicable in patients at risk; monitor for signs/symptoms of thrombosis and assess blood viscosity in patients with hyperviscosity risk
Renal Dysfunction/Acute Renal Failure
renal dysfunction, acute renal failure, osmotic nephrosis, and death reported with intravenous immune globulin (IVIG) use; patients predisposed to acute renal failure including those with pre-existing renal impairment, diabetes mellitus, volume depletion, sepsis, paraproteinemia, >65 yo, or receiving nephrotoxic drugs; ensure adequate hydration before administration; administer IVIG at minimum dose and lowest infusion rate practicable in patients at risk; IVIG products containing sucrose as stabilizer accounted for disproportionate share of renal dysfunction/failure cases; this product does not contain sucrose
Adult Dosing .
Dosage forms: INJ
Special Note
- [drug name clarification]
- Info: nonproprietary name = immune globulin human-kthm
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing
primary immunodeficiency
- [300-800 mg/kg/dose IV q3-4wk]
- Info: adjust dose based on trough IgG levels and clinical response; give 400 mg/kg/dose IV x1 ASAP if measles exposure; if maintenance dose <400 mg/kg/dose IV q3-4wk and measles exposure risk, give 400 mg/kg/dose IV x1 just prior to exposure
idiopathic thrombocytopenic purpura (off-label)
- [1000 mg/kg/dose IV x1 on day 1, may give additional dose x1 on subsequent day]
- Alt: 400 mg/kg/dose IV qd x5 days; Info: may repeat q3-4wk prn
secondary immunodeficiency, B-CLL associated (off-label)
- [400 mg/kg/dose IV q3-4wk]
chronic inflammatory demyelinating polyneuropathy (off-label)
- [1000 mg/kg/dose IV q3wk]
- Start: 2000 mg/kg/total dose IV divided over 2-5 days, infused daily; Alt: 500 mg/kg/dose IV qd x2 days, given q3wk
myasthenia gravis (off-label)
- [400 mg/kg/dose IV qd x5 days]
- Max: 1000 mg/kg/day; Alt: 1000 mg/kg/dose IV qd x2 days
renal dosing
- [see below]
- renal impairment: not defined, caution advised; Info: use minimum dose and infusion rate practicable
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.